Healthcare costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.
Although infection with the hepatitis C virus increases healthcare costs overall, the specific impact of the diseases progressive severity on healthcare costs has previously not been well studied.
"The severity of hepatitis C-related liver disease increases with age, and the aging hepatitis C population is likely to increase the economic burden of the infection on our health care system, says Stuart C. Gordon, MD, director of hepatology at Henry Ford Hospital and lead author of the study.
The results of the study will be presented at the 62nd annual meeting of the American Association for the Study of Liver Diseases in San Francisco this week.
It is estimated that the majority of the 4 million Americans with chronic hepatitis C virus infection remain undiagnosed and thus untreated. The increasing disease prevalence has created an aging population of patients with chronic hepatitis C infection and a resultant increase in the number of patients with cirrhosis, and, subsequently, the complications of cirrhosis (end-stage liver disease).
The Henry Ford study compared the economic burden for U.S. patients with chronic hepatitis C stratified by severity of liver disease in a large private health insurance claims database from 2003 to 2010. The database included claims for all prescription medications and all medical services submitted for payment.
Researchers looked at 53,796 patients with chronic hepatitis C: 41,858 (78 percent) without cirrhosis, 3,718 (7 percent) with compensated cirrhosis, and 8,220 (15percent) with end-stage liver disease. Mean age was 49 years, 51 years and 52 years respectively.
Mean healthcare costs (per month) were 32 percent and 247 percent higher for patients with compensated cirrhosis ($1,870) and end-stage liver disease ($4,931), compared to those without cirrhosis ($1,420) and these results were independent of age.
A similar trend is apparent for mean hepatitis C-related health care costs. Overall, 56 percent of total costs were hepatitis C-related and this proportion increased with disease severity (46 percent, 57 percent, and 71 percent for patients without cirrhosis, compensated cirrhosis, and end-stage liver disease, respectively).
Pharmacy, ambulatory, and inpatient care accounted for 90 percent of costs for hepatitis C patients without cirrhosis and 93 percent of the costs for those with compensated cirrhosis and end-stage liver disease.
The study estimated the annual healthcare costs to be $24,176 for patients with chronic hepatitis C infection. When looked at by disease stage, average annual costs were estimated to be $17,277 among patients with no cirrhosis, $22,752 among patients with compensated cirrhosis, and $59,995 annually among patients with end-stage liver disease.
Gordon indicated that the primary drivers of higher health care expenses were found to be inpatient costs for patients with end-stage liver disease and pharmacy costs for patients with compensated cirrhosis.
As we see patients with more advanced liver disease, we see significantly more costs to the system. The key, therefore, is to treat and cure the infection early to prevent the consequences of more advanced disease and the associated economic burden, says Gordon.
Current treatment for hepatitis C involves a cocktail of three drugs taken for 24-48 weeks with viral clearance cure rates of 65 percent to 80 percent.
Most people who are infected with hepatitis C remain without symptoms for years. The infection may lead to scarring of the liver (cirrhosis), liver cancer, the need for liver transplant, and potentially death
The study was funded by Genentech.